Contact and Impressum

Are you interested in joining us, collaborating with us or do you have any comments?

Email: [email protected]

 

Information pursuant to section 5 of the German Telemedia Act (Telemediengesetz) 

Phage41Health - The Phage Therapy Consortium

856764 Oberschleissheim

Professor Otto Hupp Str. 15

Deutschland

 

Represented by:

Dr. Joachim J. Bugert

 

Disclaimer

Phage41Health - The Phage Therapy Consortium cannot be held responsible or liable for the accuracy, completeness, up-to-dateness, or quality of the content posted.

Phage41Health - The Phage Therapy Consortium hereby disclaims liability for any loss, damage or other consequences that may arise from direct or indirect use of the website content. Individuals accessing this website do so at their own risk.

Phage41Health - The Phage Therapy Consortium reserves the right, at its sole discretion, to modify, alter or otherwise update or delete parts of its web pages or terminate publication thereof temporarily or permanently at any time without further notice.

Despite careful scrutiny, Phage41Health - The Phage Therapy Consortium cannot be held liable for the content of external links provided on this website. The proprietors of any such linked pages are solely responsible and liable for their content.

 

Layout-Template

Phage41Health - The Phage Therapy Consortium  webpages were constructed using  Drupal, a free and open-source web content management system (CMS) written in PHP and distributed under the GNU General Public License, stable version 9.2.7/ 2021-10-06.

 

CV Dr Bugert

Image removed.    *13.12.1963

 

Current position: Bundeswehr Institute of Microbiology (IMB), Phage laboratory
Deputy Director IMB, Laboratory Group Leader and Chief of Virology

Neuherbergstr. 1, 80937 München; Tel: +49 89 9926923277

Email: [email protected]

 

Curriculum vitae

 

1985 – 1991       Medical studies - Ruprechts-Karl University of Heidelberg (RKU HD), Germany.

1987 – 1994       Doctoral dissertation in Exp. Virologie - RKU HD, Germany.

1992 – 1993       Junior House Officer in Gastroenterology/ Inf. Diseases - RKU HD, Germany.

1994 – 1996       Post-Doctoral Fellow - NIH, NIAID, LVD (B. Moss), Bethesda, MD, U.S.A..

1996 – 2003       Registrar in Virology - University Hospital, Heidelberg (UHD), Germany.

1999 – 2016       Reserve Medical Officer - incl. Bernard Nocht Institute, Hamburg, Germany.

1999 –                   Consultant Microbiologist/Virologist - training for registration, UHD. Registered 2006.

2001 –                   Lecturer (ext.) - Faculty of Medicine, RKU HD, Germany.

2003 – 2016       Senior Lecturer (Assoc. Professor) - Dept. of Med. Microbiology, Cardiff University, Wales, UK.

2007 –                   Subject Editor - (human viruses), from 5/2011 co-Editor-in-Chief VIRUS GENES.

2016 –                   Surgeon CDR (JMS-Navy), from 2020 Deputy Director, Bundeswehr Institute of Microbiology.

 

Phage Research

 

1985 1994       Use of M13 & Lambda phages in doctoral dissertation 'Molecular genetics of poxviruses'.

2003 2016       Collaboration with T. Walsh and M. Toleman: bacteriophage specific for multiresistant gram negative E coli (NDM - type carbapenemase resistance).  ESCMID presentation and EID paper on NDM gram negative  prevalence in Bangladesh.

2016                    Isolation & characterization of bacteriophage targetting 3/4MRGN Klebsiella pneumoniae (Kp). In vitro packaging with Kilian Vogele (TUM- INVITRIS spin-off). Phage therapy research with J. Hammerl (BfR), C. Willy (BwKrhs Berlin), S. Kiljunen (U Helsinki, Finland), M. Clokie - A. Millard, UL-UK, and colleagues at WRAIR (B. Swiercziewski), U.S.A. Papers on MRGN 4 Kp in Tunisia and specific TUN1 podophage (1), phage pipeline for compassionate use protocols (2), in vitro packaging of Kp phage (3), nanoluc recombinant Kp reporterphage based on TUN1 (4), Kp specific jumbophage (5), further work on Kp host range extended podophage (Appleman procedure) in progress.

2017                    Phage group at IMB with BSc, MSc, and doctoral students (cadet physicians J. Stender/ N. Jakob) - IMB technical support. 

 

Phage network and funding

 

2017                  IMB Phage group funded by German Foreign Ministry Biosecurity mission to Tunisia, Biodefense program at IMB), and Deutsches Zentrum für Infektionsforschung (DZIF; DZIF - MD stipend).  

2018                    Phage editorship established at VIRUS GENES - first phage editor: Andy Millard.

2019                  Phage therapy network (https://phage4-1health.org/; consortium journal VIRUS GENES) established with C. Willy, J. Hammerl, K. Vogele, A. Millard, S. Kiljunen and S. Würstle.

2021                    Membership of NATO STO RTG-HFM 313 (2019-2024)- 'Phage therapy in military medicine' - Chairs J.-P. Pirnay and C. Willy.

2022                    Phage research funding applications to JPI-AMR, SPRIND, and European Defense Fund.       

 

Phage publications - 5 recent   (JJB  Citations: 1598, h-index 21. https://orcid.org/0000-0002-0556-3211)

 

  1. Eckstein S, Stender J, Mzoughi S, Vogele K, Kühn J, Friese D, Bugert C, Handrick S, Ferjani M, Wölfel R, Millard A, Ben Moussa M, and Bugert JJ. Isolation and characterization of lytic phage TUN1 specific for Klebsiella pneumoniae K64 clinical isolates from Tunisia. BMC Microbiol. 2021 Jun 21;21(1):186. doi: 10.1186/s12866-021-02251-w. PMID: 34154528; PMCID: PMC8215767.
  2. Practical Assessment of an Interdisciplinary Bacteriophage Delivery Pipeline for Personalized Therapy of Gram-Negative Bacterial Infections. S.Würstle, J. Stender, J.- A. Hammerl, K. Vogele, K. Rothe, C. Willy, and J.J. Bugert. MDPI Pharmaceuticals. 2022. Accepted.
  3. Emslander Q,  Vogele K, Braun P,  Stender J, Joppich M, Abele M, Meng C, Ludwig C , Bugert JJ, Willy C, Simmel FC, and Westmeyer G. Personalized Production, Non-Genomic Engineering, and Time-Resolved Proteomics of Therapeutic Phages for Biohazardous and Multidrug-Resistant Bacteria. Preprint: http://dx.doi.org/10.2139/ssrn.3887804
  4. Expression of nanoluciferase in a podovirus based reporterphage and use for high sensitivity detection Klebsiella pneumoniae in clonical material.  Hollenbeck J, Bugert JJ  and Eckstein S. VIRUS GENES  submitted.
  5. Potential of giant phage muc347 for the treatment of infections with multidrug-  resistant Klebsiella pneumoniae. Stender J, Friese D, Vogele K, Kiljunen S, Bugert JJ, and Hammerl J. Gesellschaft für Virologie Abstrakt 242 - München 30.3.-2.4.2022. Manuscript in preparation.